Provided by Tiger Trade Technology Pte. Ltd.

Evogene

0.5590
-0.0035-0.62%
Post-market: 0.5530-0.0060-1.07%16:12 EDT
Volume:190.88K
Turnover:106.00K
Market Cap:8.83M
PE:-0.61
High:0.5754
Open:0.5672
Low:0.5456
Close:0.5625
52wk High:1.50
52wk Low:0.3700
Shares:15.80M
Float Shares:9.18M
Volume Ratio:0.50
T/O Rate:2.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9114
EPS(LYR):-1.0776
ROE:-171.75%
ROA:-32.89%
PB:-3.47
PE(LYR):-0.52

Loading ...

Evogene schedules first-quarter results conference call

Reuters
·
May 07

Evogene price target raised to $2.25 from $1.75 at Alliance Global

TIPRANKS
·
Apr 13

Evogene files Form 3 for VP Finance Polina Ravzin initial beneficial ownership statement

Reuters
·
Apr 10

Evogene Reports Receipt Of Nasdaq Minimum Bid Price Notification

Reuters
·
Apr 03

Evogene Faces Nasdaq Minimum Bid Price Deficiency, Granted Cure Period to September 2026

TIPRANKS
·
Apr 03

Evogene receives Nasdaq minimum bid price notification

TIPRANKS
·
Apr 03

Evogene gets Nasdaq notice as shares trade below $1 minimum bid price

Reuters
·
Apr 03

Evogene unit Casterra reports successful mechanized castor field trials in Brazil

Reuters
·
Apr 01

Evogene files to sell 5.08M ordinary shares for holders

TIPRANKS
·
Mar 27

Evogene Director Leon Recanati Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Evogene Ltd. Director Nimrodi Nir Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Evogene Ltd. Director Percy Adrian John Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Evogene names Gabi Tarcic as Chief Development Officer in initial beneficial ownership filing

Reuters
·
Mar 18

Evogene names Ilia Zhidkov as Chief Technology Officer in initial beneficial ownership filing

Reuters
·
Mar 18

Evogene Ltd. director Sarit Firon files initial beneficial ownership statement

Reuters
·
Mar 18

Evogene Files Form 3 Initial Beneficial Ownership Statement for CFO Eldad Yaron

Reuters
·
Mar 18

Evogene files Form 3 for President and CEO Haviv Ofer

Reuters
·
Mar 18

Evogene Ltd. files Form 3 initial beneficial ownership statement for Director Falk Dan Michael

Reuters
·
Mar 18

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

TIPRANKS
·
Mar 13

Evogene Earnings Call: AI Ambition Meets Cash Reality

TIPRANKS
·
Mar 07